(Q41172065)

27 September 2017

1 reference

title

Pharmacologic considerations for antiviral drug development (English)

1 reference

27 September 2017

C V Fletcher

1

1 reference

27 September 2017

language of work or name

English

0 references

publication date

1 September 1996

1 reference

Annals of Pharmacotherapy

27 September 2017

published in

1 reference

27 September 2017

volume

30

1 reference

27 September 2017

issue

9

1 reference

27 September 2017

page(s)

972-977

1 reference

Studying treatments for AIDS: new challenges for clinical trials--a panel discussion at the 1990 annual meeting of the Society for Clinical Trials

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Mechanism of action and selectivity of acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-) enantiomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Effect of acyclovir on the proliferation of human fibroblasts and peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Effect of acyclovir and interferon on human hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Dextran sulfate is poorly absorbed after oral administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Effect of fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Acyclovir therapy in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Epidemiology of genital herpes simplex virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Design of an individualized fixed-dose clinical trial to test the antiepileptic efficacy of a plasma flunarizine concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

The randomized concentration-controlled trial: An evaluation of its sample size efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Foscarnet for suppression of human immunodeficiency virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Continuous infusion of high-dose acyclovir for serious herpesvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000912

10.1177/106002809603000912

21 January 2018

Identifiers

DOI

1 reference

27 September 2017

1 reference